Jodie Morrison
Board Member
immunology
M?dicago Inc
Antarctica
Biography
Ms. Morrison has 20 years of broad experience in the pharmaceutical and biotech industries, including extensive operational and development leadership. She is currently the chief executive officer (CEO) and president of eGenesis. From 2006 to 2017, Ms. Morrison held positions of increasing responsibility at Tokai Pharmaceuticals, including serving her last 4 years as president and chief executive officer and a member of its board of directors. Prior to being appointed CEO, she served as Tokai’s chief operating officer and head of clinical affairs. Throughout her tenure at Tokai she oversaw the company’s development pipeline and led it’s operational management, including the execution of the $105M IPO and completion of the merger forming Novus Therapeutics in 2017. Prior to joining Tokai, Ms. Morrison was director of clinical operations and medical affairs at Dyax Corporation where she built and led the clinical development teams for the Kalbitor™ (hereditary angioedema) program. Before joining Dyax, she held clinical management positions at Curis, Inc. and Diacrin, Inc. Ms. Morrison has a B.A. in neuroscience from Mount Holyoke College, business training from the Greater Boston Executive Program at MIT Sloan School of Management and clinical research certification from Boston University School of Medicine. In addition to her appointment at Keryx, Ms. Morrison currently sits on the board of directors for Aileron Therapeutics (ALRN) and Novus Therapeutics (NVUS).
Research Interest
Ms. Morrison has 20 years of broad experience in the pharmaceutical and biotech industries, including extensive operational and development leadership. She is currently the chief executive officer (CEO) and president of eGenesis. From 2006 to 2017, Ms. Morrison held positions of increasing responsibility at Tokai Pharmaceuticals, including serving her last 4 years as president and chief executive officer and a member of its board of directors. Prior to being appointed CEO, she served as Tokai’s chief operating officer and head of clinical affairs. Throughout her tenure at Tokai she oversaw the company’s development pipeline and led it’s operational management, including the execution of the $105M IPO and completion of the merger forming Novus Therapeutics in 2017. Prior to joining Tokai, Ms. Morrison was director of clinical operations and medical affairs at Dyax Corporation where she built and led the clinical development teams for the Kalbitor™ (hereditary angioedema) program. Before joining Dyax, she held clinical management positions at Curis, Inc. and Diacrin, Inc. Ms. Morrison has a B.A. in neuroscience from Mount Holyoke College, business training from the Greater Boston Executive Program at MIT Sloan School of Management and clinical research certification from Boston University School of Medicine. In addition to her appointment at Keryx, Ms. Morrison currently sits on the board of directors for Aileron Therapeutics (ALRN) and Novus Therapeutics (NVUS).
